Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

See Remarks

President & CEO

Chief Financial Officer

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for p...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-01-19	Premium	acquired	Premium	Premium	Premium	See Remarks
2024-01-19	Premium	sold	Premium	Premium	Premium	See Remarks
2023-12-19	Premium	acquired	Premium	Premium	Premium	See Remarks
2023-12-19	Premium	sold	Premium	Premium	Premium	See Remarks
2023-11-20	Premium	acquired	Premium	Premium	Premium	See Remarks
2023-11-20	Premium	sold	Premium	Premium	Premium	See Remarks
2023-10-19	Premium	acquired	Premium	Premium	Premium	See Remarks
2023-10-19	Premium	sold	Premium	Premium	Premium	See Remarks
2023-09-19	Premium	sold	Premium	Premium	Premium	See Remarks
2023-09-19	Premium	acquired	Premium	Premium	Premium	See Remarks
2023-08-21	Premium	acquired	Premium	Premium	Premium	See Remarks
2023-08-21	Premium	sold	Premium	Premium	Premium	See Remarks
2023-07-19	Premium	acquired	Premium	Premium	Premium	See Remarks
2023-07-19	Premium	sold	Premium	Premium	Premium	See Remarks
2023-06-20	Premium	acquired	Premium	Premium	Premium	See Remarks
2023-06-20	Premium	sold	Premium	Premium	Premium	See Remarks
2023-05-19	Premium	acquired	Premium	Premium	Premium	See Remarks
2023-05-19	Premium	sold	Premium	Premium	Premium	See Remarks
2022-10-19	Premium	bought	Premium	Premium	Premium	President & CEO
2022-10-18	Premium	bought	Premium	Premium	Premium	See Remarks
2022-10-18	Premium	bought	Premium	Premium	Premium	-
2022-10-18	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2022-10-18	Premium	bought	Premium	Premium	Premium	President & CEO
2022-10-18	Premium	bought	Premium	Premium	Premium	-
2022-10-18	Premium	bought	Premium	Premium	Premium	-

CABA - Cabaletta Bio Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for CABA